• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AVACEN Medical seeks buyer

AVACEN Medical seeks buyer

December 22, 2015
CenterWatch Staff

AVACEN Medical today announced it has formally retained Objective Capital Partners to locate a qualified purchaser to acquire the company.

San Diego-based AVACEN Medical is a company involved in research and development related to medical devices designed to use its patented AVACEN Treatment Method. Its FDA-cleared AVACEN 100 product is an over-the-counter Class II medical device that addresses the medical needs of over 1 billion people worldwide.

Developed over a six-year period, the AVACEN 100—with more than 3,000 firmware instructions—is the world’s first noninvasive family medical device designed to allow users to easily treat their entire body. It has a record of about 500,000 treatments without a single reported negative side effect.

According to CEO Thomas G. Muehlbauer, “Our patented AVACEN Treatment Method is an entirely new concept in microcirculation therapy. This is accomplished by safely and noninvasively increasing core body temperature by infusing heat into the palm of the hand. Almost everything that can go wrong with the body, including aging, can be traced to compromised microcirculation. Our device and patents address the alleviation of symptoms associated with an autoimmune, circulatory, neurological, lymphatic, thermoregulatory disorder, or endocrinal dysfunction, or any combination thereof.

“Of the alternatives we explored, the company has determined it is in the best interest of its shareholders to offer itself as an acquisition target to a buyer that possesses the necessary resources to advance our fields of use and support the worldwide demand for the company’s products. We believe this is the most advantageous and quickest path to secure our $10 billion annual sales potential while the 17-year average remaining term of our U.S. and international patents is most favorable.”

AVACEN Medical recently announced that ClinicalTrials.gov, a service of the NIH, has published the results of the company’s AVACEN Treatment Method clinical trials. The study was conducted by the University of California, San Diego and the Department of Veterans Affairs. The study results, published in the Society for Neuroscience annual meeting and poster program, indicate a major benefit for fibromyalgia sufferers using the AVACEN Treatment Method. The data show a statistically significant reduction in widespread pain of more than 40%, and a decrease in tender point count to a level below the value typically used for the clinical assessment of fibromyalgia.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing